Abstract | AIMS: MAIN METHODS: The effects of hydralazine in AKI-to-CKD transition were also evaluated. Human renal proximal tubular epithelial cells were stimulated by I/R conditions in vitro. To generate a mouse model of AKI, a right nephrectomy was performed, followed by left renal pedicle I/R using a small atraumatic clamp. KEY FINDINGS: In the in vitro part, hydralazine could protect renal proximal tubular epithelial cells against insults from the I/R injury through XO/ NADPH oxidase inhibition. In the in vivo part, hydralazine preserved renal function in AKI mice and improved the AKI-to-CKD transition by decreasing renal glomerulosclerosis and fibrosis independently of blood pressure lowering. Furthermore, hydralazine exerted antioxidant, anti-inflammatory, and anti-fibrotic effects both in vitro and in vivo. SIGNIFICANCE:
Hydralazine, as a XO/ NADPH oxidase inhibitor, could protect renal proximal tubular epithelial cells from the insults of I/R and prevent kidney damage in AKI and AKI-to-CKD. The above experimental studies strengthen the possibility of repurposing hydralazine as a potential renoprotective agent through its antioxidative mechanisms.
|
Authors | Chih-Hung Chiang, Ching Chen, Shih-Ying Fang, Su-Chu Lin, Jaw-Wen Chen, Ting-Ting Chang |
Journal | Life sciences
(Life Sci)
Vol. 327
Pg. 121863
(Aug 15 2023)
ISSN: 1879-0631 [Electronic] Netherlands |
PMID | 37331504
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Elsevier Inc. All rights reserved. |
Chemical References |
- Xanthine Oxidase
- NADPH Oxidases
- Hydralazine
- Enzyme Inhibitors
|
Topics |
- Mice
- Humans
- Animals
- Xanthine Oxidase
- NADPH Oxidases
- Renal Insufficiency, Chronic
(pathology)
- Acute Kidney Injury
(drug therapy, prevention & control, pathology)
- Kidney
(pathology)
- Hydralazine
(pharmacology)
- Enzyme Inhibitors
(pharmacology)
- Inflammation
(pathology)
- Reperfusion Injury
(pathology)
- Fibrosis
|